^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SC-006

    i
    Other names: SC-006, SC006, SC 006
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    DNA replication inhibitor, RNF43-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    over4years
    [VIRTUAL] First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer (AACR-II 2020)
    SC-006 dose escalation was limited by thrombocytopenia observed below the predicted efficacious dose, leading to study termination.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    RNF43 (Ring Finger Protein 43)
    |
    budigalimab (ABBV-181) • SC-006